Letter to the Editor

Low levels of *BNIP3* promoter hypermethylation in invasive breast cancer

Dear Sir,

Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (*BNIP3*) is a pro-apoptotic member of the Bcl-2 family induced under hypoxia [3,5,6]. Low or absent expression has been described in several human tumors, resulting in poor prognosis [1]. We previously reported that *BNIP3* expression is lost in a significant portion of invasive breast cancers, which was correlated with poor prognostic features such as positive lymph node status and high proliferation [9]. Since DNA promoter hypermethylation (“methylation”) is a common mechanism to silence gene expression, contributing to tumor-progression and invasion, we further studied the relation between *BNIP3* methylation and gene expression by RNA *in situ* hybridization (ISH) in invasive breast cancer.

In 40 cases of invasive breast cancer, *BNIP3* methylation was studied by Methylation Specific Multiplex Ligation-dependent Probe Amplification [2,4,8,11] with 2 *BNIP3* probes (157 and 291) located in the CpG island harboring the *BNIP3* promoter. The 157 probe is located 50 nucleotides before exon 1, while probe 291 is located in exon 1. Both probes target sequences located in the *BNIP3* promoter that is located within a 1700-bp CpG island, which spans from –1162 to +538 bp of the transcription start site and contains the first exon of the *BNIP3* gene. This promoter area has been reported to be methylated in pancreatic cancer [12] and in gastric and colorectal cancer [10]. Data on *BNIP3* mRNA *in situ* hybridization were derived from a previous study [9].

BNIP3 methylation levels in 8 normal tissue samples was on average 0.08. *BNIP3* methylation was overall low (between 0.3 and 15% for probe 157 and between 0 and 31% for probe 291), while other genes included in this assay (*CCND2*, *RASSF1*, *GSTP1*, *HIN1*) showed methylation percentages up to 100% (means 24–51%) in the same tumors. Cases that were negative ($N = 4$) in *BNIP3* RNA ISH showed higher *BNIP3*

Fig. 1. Relation between *BNIP3* promoter hypermethylation (probe 157) and *BNIP3* RNA expression by *in situ* hybridization (4 cases were negative and 36 positive).

methylation ($p = 0.047$) for probe 157 than those positive by RNA ISH ($N = 36$) (see Fig. 1), but in none of the ISH negative tumors the methylation levels exceeded 10%. This correlation therefore needs to be interpreted with care. *BNIP3* methylation levels as detected by probe 291 were not significantly different ($p = 0.83$) between tumors with and without *BNIP3* expression.

In conclusion, *BNIP3* shows low levels of promoter hypermethylation in invasive breast cancer, mostly lower than the proposed 15% threshold that supposedly discriminates “true” from background methylation [7]. Although *BNIP3* methylation detected with probe 157 is associated with lower *BNIP3* expression at the RNA level, its low level suggests that methylation does not seem to be a major explanation for the differential *BNIP3* expression in invasive breast cancer previously described [9].

Acknowledgements

Supported by the Dutch Cancer Society, project UU 2006-3710. We thank Dr. Theo van Laar for previous input into this project and Dick van Wichen for technical assistance.

Paul J. van Diest^{a,*}, Karijn P.M. Suijkerbuijk^a,
Esther A. Koop^a, Roel A. de Weger^a
and Elsken van der Wall^b

^a*Department of Pathology, University Medical
Center Utrecht, Utrecht, The Netherlands*

^b*Division of Internal Medicine and Dermatology,
Medical Center Utrecht, Utrecht, The Netherlands*

*Corresponding author: Prof. Paul J. van Diest, MD, PhD, Department of Pathology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. Tel.: +31 88 7556 565; Fax: +31 30 2544 990; E-mail: p.j.vandiest@umcutrecht.nl.

References

- [1] G. Bellot, R. Garcia-Medina, P. Gounon, J. Chiche, D. Roux, J. Pouyssegur and N.M. Mazure, Hypoxia-induced autophagy is mediated through HIF-induction of BNIP3 and BNIP3L via their BH3-domains, *Mol. Cell Biol.* **29**(10) (2009), 2570–2581.
- [2] G.M. Bol, K.P.M. Suijkerbuijk, J. Bart, M. Vooijs, E. van der Wall and P.J. van Diest, Methylation profiles of hereditary and sporadic ovarian cancer, *Histopathology* **57** (2010), 363–370.
- [3] R.K. Bruick, Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia, *Proc. Natl. Acad. Sci. USA* **97**(16) (2000), 9082–9087.
- [4] J. Coffa, M.A. van de Wiel, B. Diosdado, B. Carvalho, J. Schouten and G.A. Meijer, MLPAlyzer: data analysis tool for reliable automated normalization of MLPA fragment data, *Cell Oncol.* **30** (2008), 323–335.
- [5] A.E. Greijer, P. van der Groep, D. Kemming, A. Shvarts, G.L. Semenza, G.A. Meijer, M.A. van de Wiel, J.A. Belien, P.J. van Diest and E. van der Wall, Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1), *J. Pathol.* **206**(3) (2005), 291–304.
- [6] K. Guo, G. Searfoss, D. Krolkowski, M. Pagnoni, C. Franks, K. Clark, K.T. Yu, M. Jaye and Y. Ivashchenko, Hypoxia induces the expression of the pro-apoptotic gene BNIP3, *Cell Death Differ.* **8**(4) (2001), 367–376.
- [7] A. Gylling, W.M. Abdel-Rahman, M. Juhola, K. Nuorva, E. Hautala, H.J. Järvinen, J.P. Mecklin, M. Aarnio and P. Peltomäki, Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study, *Gut* **56** (2007), 926–933.
- [8] C.J. Hess, N. Ameziane, G.J. Schuurhuis, A. Errami, F. Denkers, G.J. Kaspers, J. Cloos, H. Joenje, D. Reinhardt, G.J. Ossenkoppele, C.M. Zwaan and Q. Waisfisz, Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia, *Cell Oncol.* **30** (2008), 299–306.
- [9] E.A. Koop, T. van Laar, D.F. van Wichen, R.A. de Weger, E. Wall and P.J. van Diest, Expression of BNIP3 in invasive breast cancer: correlations with the hypoxic response and clinicopathological features, *BMC Cancer* **9** (2009), 175.
- [10] M. Murai, M. Toyota, H. Suzuki, A. Satoh, Y. Sasaki, K. Akino, M. Ueno, F. Takahashi, M. Kusano, H. Mita, K. Yanagihara, T. Endo, Y. Hinoda, T. Tokino and K. Imai, Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer, *Clin. Cancer Res.* **11** (2005), 1021–1027.
- [11] A.O.H. Nygren, N. Ameziane, H.M.B. Duarte, R.N. Vijzelaar, Q. Waisfisz, C.J. Hess, J.P. Schouten and A. Errami, Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences, *Nucl. Acids Res.* **33**(14) (2005), e128.
- [12] J. Okami, D.M. Simeone and C.D. Logsdon, Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer, *Cancer Res.* **64** (2004), 5338–5346.